Key genes associated with pancreatic cancer and their association with outcomes: A bioinformatics analysis

Wu,Jiajia; Li,Zedong; Zeng,Kai; Wu,Kangjian; Xu,Dong; Zhou,Jun; Xu,Lijian

doi:10.3892/mmr.2019.10321

Key genes associated with pancreatic cancer and their association with outcomes: A bioinformatics analysis

Authors:
- Jiajia Wu
- Zedong Li
- Kai Zeng
- Kangjian Wu
- Dong Xu
- Jun Zhou
- Lijian Xu
View Affiliations

Affiliations: Department of General Surgery, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210000, P.R. China, Department of Minimally Invasive Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, P.R. China, Department of General Surgery, Gaochun People's Hospital, Nanjing, Jiangsu 211300, P.R. China
Published online on: June 3, 2019 https://doi.org/10.3892/mmr.2019.10321
Pages: 1343-1352

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pancreatic cancer is a highly malignant neoplastic disease of the digestive system. In the present study, the dataset GSE62165 was downloaded from the Gene Expression Omnibus (GEO) database. GSE62165 contained the data of 118 pancreatic ductal adenocarcinoma samples (38 early‑stage tumors, 62 lymph node metastases and 18 advanced tumors) and 13 control samples. Differences in the expression levels of genes between normal tissues and early‑stage tumors were investigated. A total of 240 differentially expressed genes (DEGs) were identified using R software 3.5 (137 upregulated genes and 103 downregulated genes). Then, the differentially expressed genes were subjected to Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analysis. The following 18 core genes were identified using Cytoscape, based on the protein‑interaction network of DEGs determined using the online tool STRING: EGF, ALB, COL17A1, FN1, TIMP1, PLAU, PLA2G1B, IGFBP3, PLAUR, VCAN, COL1A1, PNLIP, CTRL, PRSS3, COMP, CPB1, ITGA2 and CEL. The pathways of the core genes were primarily associated with pancreatic secretion, protein digestion and absorption, and focal adhesion. Finally, survival analyses of core genes in pancreatic cancer were conducted using the UALCAN online database. It was revealed that PLAU and COL17A1 were significantly associated with poor prognosis (P<0.05). The expression levels of genes in primary pancreatic cancer tissues were then compared; only one gene, COL17A1, was identified to be significantly differentially expressed. Finally, another dataset from GEO, GSE28735, was analyzed to verify the upregulated expression of COL17A1. Taken together, the results of the present study have indicated that the expression of COL17A1 gene may be associated with the occurrence and development of pancreatic cancer.

View Figures

View References

1	Kamisawa T, Wood LD, Itoi T and Takaori K: Pancreatic cancer. Lancet. 388:73–85. 2016. View Article : Google Scholar : PubMed/NCBI
2	Michaud D: Epidemiology of pancreatic cancer. Minerva Chir. 59:99–111. 2004.PubMed/NCBI
3	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
4	Risch HA: Etiology of pancreatic cancer, with a hypothesis concerning the role of N-nitroso compounds and excess gastric acidity. J Natl Cancer Inst. 95:948–960. 2003. View Article : Google Scholar : PubMed/NCBI
5	Kern SE, Shi C and Hruban RH: The complexity of pancreatic ductal cancers and multidimensional strategies for therapeutic targeting. J Pathol. 223:295–306. 2011. View Article : Google Scholar : PubMed/NCBI
6	Grasso C, Jansen G and Giovannetti E: Drug resistance in pancreatic cancer: Impact of altered energy metabolism. Crit Rev Oncol Hematol. 114:139–152. 2017. View Article : Google Scholar : PubMed/NCBI
7	Eskelinen M and Haglund U: Developments in serologic detection of human pancreatic adenocarcinoma. Scand J Gastroenterol. 34:833–844. 1999. View Article : Google Scholar : PubMed/NCBI
8	Bass AJ, Lawrence MS, Brace LE, Ramos AH, Drier Y, Cibulskis K, Sougnez C, Voet D, Saksena G, Sivachenko A, et al: Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nat Genet. 43:964–968. 2011. View Article : Google Scholar : PubMed/NCBI
9	Sjöblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, et al: The consensus coding sequences of human breast and colorectal cancers. Science. 314:268–274. 2006. View Article : Google Scholar : PubMed/NCBI
10	Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, et al: The genomic landscapes of human breast and colorectal cancers. Science. 318:1108–1113. 2007. View Article : Google Scholar : PubMed/NCBI
11	Janky R, Binda MM, Allemeersch J, Van den Broeck A, Govaere O, Swinnen JV, Roskams T, Aerts S and Topal B: Prognostic relevance of molecular subtypes and master regulators in pancreatic ductal adenocarcinoma. BMC Cancer. 16:6322016. View Article : Google Scholar : PubMed/NCBI
12	Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH, Sherman PM, Holko M, et al: NCBI GEO: Archive for functional genomics data sets-update. Nucleic Acids Res 41 (Database Issue). D991–D995. 2013.
13	Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W and Smyth GK: Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43:e472015. View Article : Google Scholar : PubMed/NCBI
14	Zhang G, Schetter A, He P, Funamizu N, Gaedcke J, Ghadimi BM, Ried T, Hassan R, Yfantis HG, Lee DH, et al: DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity and predicts clinical outcome in pancreatic ductal adenocarcinoma. PLoS One. 7:e315072012. View Article : Google Scholar : PubMed/NCBI
15	Zhang G, He P, Tan H, Budhu A, Gaedcke J, Ghadimi BM, Ried T, Yfantis HG, Lee DH, Maitra A, et al: Integration of metabolomics and transcriptomics revealed a fatty acid network exerting growth inhibitory effects in human pancreatic cancer. Clin Cancer Res. 19:4983–4993. 2013. View Article : Google Scholar : PubMed/NCBI
16	Xing Z, Chu C, Chen L and Kong X: The use of Gene Ontology terms and KEGG pathways for analysis and prediction of oncogenes. Biochim Biophys Acta. 1860:2725–2734. 2016. View Article : Google Scholar : PubMed/NCBI
17	Kanehisa M, Sato Y, Furumichi M, Morishima K and Tanabe M: New approach for understanding genome variations in KEGG. Nucleic Acids Res. 47:D590–D595. 2019. View Article : Google Scholar : PubMed/NCBI
18	Kanehisa M, Furumichi M, Tanabe M, Sato Y and Morishima K: KEGG: New perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 45:D353–D361. 2017. View Article : Google Scholar : PubMed/NCBI
19	Kanehisa M and Goto S: KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28:27–30. 2000. View Article : Google Scholar : PubMed/NCBI
20	Yu G, Wang LG, Han Y and He QY: clusterProfiler: An R package for comparing biological themes among gene clusters. OMICS. 16:284–287. 2012. View Article : Google Scholar : PubMed/NCBI
21	Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
22	Chin CH, Chen SH, Wu HH, Ho CW, Ko MT and Lin CY: cytoHubba: Identifying hub objects and sub-networks from complex interactome. BMC Syst Biol. 8 (Suppl 4):S112014. View Article : Google Scholar : PubMed/NCBI
23	Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and Varambally S: UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 19:649–658. 2017. View Article : Google Scholar : PubMed/NCBI
24	Li B and Dewey CN: RSEM: Accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics. 12:3232011. View Article : Google Scholar : PubMed/NCBI
25	Wang X, Wang L, Mo Q, Dong Y, Wang G and Ji A: Changes of Th17/Treg cell and related cytokines in pancreatic cancer patients. Int J Clin Exp Pathol. 8:5702–5708. 2015.PubMed/NCBI
26	Shen S, Gui T and Ma C: Identification of molecular biomarkers for pancreatic cancer with mRMR shortest path method. Oncotarget. 8:41432–41439. 2017.PubMed/NCBI
27	Thomas PD: The gene ontology and the meaning of biological function. Methods Mol Biol. 1446:15–24. 2017. View Article : Google Scholar : PubMed/NCBI
28	Duffy MJ, Duggan C, Mulcahy HE, McDermott EW and O'Higgins NJ: Urokinase plasminogen activator: A prognostic marker in breast cancer including patients with axillary node-negative disease. Clin Chem. 44:1177–1183. 1998.PubMed/NCBI
29	Nielsen TO, Andrews HN, Cheang M, Kucab JE, Hsu FD, Ragaz J, Gilks CB, Makretsov N, Bajdik CD, Brookes C, et al: Expression of the insulin-like growth factor I receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: Potential for intervention with 17-allylamino geldanamycin. Cancer Res. 64:286–291. 2004. View Article : Google Scholar : PubMed/NCBI
30	Pavón MA, Arroyo-Solera I, Céspedes MV, Casanova I, León X and Mangues R: uPA/uPAR and SERPINE1 in head and neck cancer: Role in tumor resistance, metastasis, prognosis and therapy. Oncotarget. 7:57351–57366. 2016. View Article : Google Scholar : PubMed/NCBI
31	Amos S, Redpath GT, Dipierro CG, Carpenter JE and Hussaini IM: Epidermal growth factor receptor-mediated regulation of urokinase plasminogen activator expression and glioblastoma invasion via C-SRC/MAPK/AP-1 signaling pathways. J Neuropathol Exp Neurol. 69:582–592. 2010. View Article : Google Scholar : PubMed/NCBI
32	Chaudhary A, Hilton MB, Seaman S, Haines DC, Stevenson S, Lemotte PK, Tschantz WR, Zhang XM, Saha S, Fleming T and St Croix B: TEM8/ANTXR1 blockade inhibits pathological angiogenesis and potentiates tumoricidal responses against multiple cancer types. Cancer Cell. 21:212–226. 2012. View Article : Google Scholar : PubMed/NCBI
33	Xu ZY, Chen JS and Shu YQ: Gene expression profile towards the prediction of patient survival of gastric cancer. Biomed Pharmacother. 64:133–139. 2010. View Article : Google Scholar : PubMed/NCBI
34	Liu P, Weng Y, Sui Z, Wu Y, Meng X, Wu M, Jin H, Tan X, Zhang L and Zhang Y: Quantitative secretomic analysis of pancreatic cancer cells in serum-containing conditioned medium. Sci Rep. 6:376062016. View Article : Google Scholar : PubMed/NCBI
35	Borradori L and Sonnenberg A: Structure and function of hemidesmosomes: More than simple adhesion complexes. J Invest Dermatol. 112:411–418. 1999. View Article : Google Scholar : PubMed/NCBI
36	Järveläinen H, Sainio A, Koulu M, Wight TN and Penttinen R: Extracellular matrix molecules: Potential targets in pharmacotherapy. Pharmacol Rev. 61:198–223. 2009. View Article : Google Scholar : PubMed/NCBI
37	Yodsurang V, Tanikawa C, Miyamoto T, Lo PHY, Hirata M and Matsuda K: Identification of a novel p53 target, COL17A1, that inhibits breast cancer cell migration and invasion. Oncotarget. 8:55790–55803. 2017. View Article : Google Scholar : PubMed/NCBI
38	Chowdhury N and Sapru S: Association of protein translation and extracellular matrix gene sets with breast cancer metastasis: Findings uncovered on analysis of multiple publicly available datasets using individual patient data approach. PLoS One. 10:e01296102015. View Article : Google Scholar : PubMed/NCBI
39	Rizwan A, Bulte C, Kalaichelvan A, Cheng M, Krishnamachary B, Bhujwalla ZM, Jiang L and Glunde K: Metastatic breast cancer cells in lymph nodes increase nodal collagen density. Sci Rep. 5:100022015. View Article : Google Scholar : PubMed/NCBI
40	Zou X, Feng B, Dong T, Yan G, Tan B, Shen H, Huang A, Zhang X, Zhang M, Yang P, et al: Up-regulation of type I collagen during tumorigenesis of colorectal cancer revealed by quantitative proteomic analysis. J Proteomics. 94:473–485. 2013. View Article : Google Scholar : PubMed/NCBI